Telangana Emerges as a Prime Destination for Pharma Investment, Attracting Leading Companies
Telangana’s strategic initiatives in fostering innovation, manufacturing excellence, and sustainable development have positioned it as a pivotal hub in the Indian pharmaceutical sector. The state’s proactive measures have drawn substantial investments from companies based in Karnataka and beyond, including major players like Biocon, Syngene, and Shilpa Medicare, who have established significant operations to leverage Telangana’s conducive business environment.
Hyderabad Pharma City, recognized as a National Investment and Manufacturing Zone (NIMZ) by the Union government, stands as the world’s largest integrated cluster for pharmaceutical industries, emphasizing both research and development capabilities and manufacturing prowess.
Kaushik Desai, a pharma consultant, highlighted Telangana’s appeal for pharmaceutical investments, citing its array of esteemed pharmacy and technical institutes, including NIPER, and its strategic location with access to sea and air transport hubs.
Dr. T V Narayana, President of the Indian Pharmaceutical Association, noted Telangana’s competitive edge in attracting pharma investments, attributing it to factors such as readily available serviced land and a skilled pool of scientific and technical talent.
Dr. JAS Giri, Chairman of the local organizing committee for the 73rd Indian Pharmaceutical Congress (IPC), outlined Hyderabad’s advantages as a host city, including globally audited pharmaceutical facilities, the presence of 120 biotech companies in Genome Valley, and established medical device clusters in Telangana and Vishakhapatnam.
In recent years, Biocon has made substantial investments totaling close to Rs. 1,000 crore across Greenfield and Brownfield projects in Telangana and Andhra Pradesh, reinforcing its commitment to expanding its footprint in the region. Similar sentiments were echoed by Shilpa Medicare’s Managing Director, Vishnukant Bhutada, who underscored Telangana’s proactive approach and supportive policies as key factors driving their investments in the state’s pharmaceutical sector.
The strategic advantages offered by Telangana, including robust infrastructure, skilled workforce availability, supportive government policies, and strategic location, continue to position the state as a preferred destination for growth and innovation in the dynamic Indian pharmaceutical landscape.